These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18193102)

  • 1. Lansoprazole-induced improvement of esophageal submucosal injury.
    Mine S; Tanaka Y
    J Clin Biochem Nutr; 2007 Sep; 41(2):92-6. PubMed ID: 18193102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
    Mine S; Fujisaki T; Tabata T; Matsuoka H; Iida T; Yamada S; Tanaka Y; Morimoto I; Eto S; Aibe T
    Am J Gastroenterol; 2000 Feb; 95(2):381-6. PubMed ID: 10685739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor.
    Mine S; Iida T; Tabata T; Okada Y; Tanaka Y
    J Gastroenterol Hepatol; 2008 Feb; 23(2):303-9. PubMed ID: 17725600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease.
    Yoshida N; Uchiyama K; Kuroda M; Sakuma K; Kokura S; Ichikawa H; Naito Y; Takemura T; Yoshikawa T; Okanoue T
    Scand J Gastroenterol; 2004 Sep; 39(9):816-22. PubMed ID: 15513378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of esophageal motility abnormalities in severe reflux esophagitis].
    Xu JY; Xie XP; Hou XH
    Zhonghua Nei Ke Za Zhi; 2005 May; 44(5):353-5. PubMed ID: 16009005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
    Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
    J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility.
    Xu JY; Xie XP; Song GQ; Hou XH
    Dis Esophagus; 2007; 20(4):346-52. PubMed ID: 17617885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esophagoprotective activity of angiotensin-(1-7) in experimental model of acute reflux esophagitis. Evidence for the role of nitric oxide, sensory nerves, hypoxia-inducible factor-1alpha and proinflammatory cytokines.
    Pawlik MW; Kwiecien S; Pajdo R; Ptak-Belowska A; Brzozowski B; Krzysiek-Maczka G; Strzalka M; Konturek SJ; Brzozowski T
    J Physiol Pharmacol; 2014 Dec; 65(6):809-22. PubMed ID: 25554985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lansoprazole plus levosulpiride versus esomeprazole in participants with gastroesophageal reflux disease and erosive esophagitis: a double blinded randomized control trial.
    Umer MR; Mejia Crespo WE; Dugan S; Javed H; Suleman M; Afzal MW; Mumtaz H; Saqib M; Malik HM; Iftikhar M
    Ann Med Surg (Lond); 2023 Oct; 85(10):4866-4876. PubMed ID: 37811050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential role of the esophageal pre-epithelial barrier components in the maintenance of integrity of the esophageal mucosa in patients with endoscopically negative gastroesophageal reflux disease.
    Marcinkiewicz M; Han K; Zbroch T; Poplawski C; Gramley W; Goldin G; Sarosiek J
    Am J Gastroenterol; 2000 Jul; 95(7):1652-60. PubMed ID: 10925964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
    Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroesophageal reflux disease and eosinophilic esophagitis in infants and children. A study of esophageal pH, multiple intraluminal impedance and endoscopic ultrasound.
    Dalby K; Nielsen RG; Kruse-Andersen S; Fenger C; Durup J; Husby S
    Scand J Gastroenterol; 2010 Sep; 45(9):1029-35. PubMed ID: 20504244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V; Ferry G; Gunasekaran T; Huang B; Keith R; Book L
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S308-18. PubMed ID: 12607791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs, bugs, and esophageal pH profiles.
    Robinson M
    Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune and Inflammatory Responses in GERD and Lansoprazole.
    Isomoto H; Nishi Y; Kanazawa Y; Shikuwa S; Mizuta Y; Inoue K; Kohno S
    J Clin Biochem Nutr; 2007 Sep; 41(2):84-91. PubMed ID: 18193101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acid reflux is a poor predictor for severity of erosive reflux esophagitis.
    Avidan B; Sonnenberg A; Schnell TG; Sontag SJ
    Dig Dis Sci; 2002 Nov; 47(11):2565-73. PubMed ID: 12452396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of gastroesophageal reflux disease.
    Guimarães EV; Marguet C; Camargos PA
    J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S133-45. PubMed ID: 17136289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients].
    Jeong YJ; Lee DH; Choi TH; Hwang TJ; Lee BH; Nah JC; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Kim N; Jung HC; Song IS
    Korean J Gastroenterol; 2010 Feb; 55(2):100-8. PubMed ID: 20168056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.